---
title: Regulatory workshop on standardisation of clinical procedures, endpoints and
  data robustness of human challenge studies - A stakeholder meeting report
date: '2025-01-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39824043/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250118170356&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Inno4Vac, a public-private partnership funded by the IMI2/EU/EFPIA Joint
  Undertaking (IMI2 JU), brings together academic institutions, SMEs, and pharmaceutical
  companies to accelerate and de-risk vaccine development. The project has made significant
  strides in the selection and production of challenge agents for influenza, respiratory
  syncytial virus (RSV), and toxigenic Clostridioides difficile for controlled human
  infection model studies (CHIMs). A regulatory workshop held on March 20, ...
disable_comments: true
---
Inno4Vac, a public-private partnership funded by the IMI2/EU/EFPIA Joint Undertaking (IMI2 JU), brings together academic institutions, SMEs, and pharmaceutical companies to accelerate and de-risk vaccine development. The project has made significant strides in the selection and production of challenge agents for influenza, respiratory syncytial virus (RSV), and toxigenic Clostridioides difficile for controlled human infection model studies (CHIMs). A regulatory workshop held on March 20, ...